Abstract
Understanding prognosis of malignant melanoma is becoming increasingly important. Firstly, the incidence of cutaneous malignant melanoma is rising rapidly [1]. There has been an 80% increase in the incidence of melanoma in the United States between 1973 and 1980 [2]. Up to one in every 200 citizens of the United States may expect to develop a melanoma during the next generation. Secondly, understanding the interplay and importance of individual prognostic factors may allow insight into the biology of the tumor. Thirdly, understanding of prognosis allows a general outline of therapy for subsets of patients with melanoma and explicit tailoring for therapy of individual patients. Lastly, although not of least importance, is the ability to give the patient some understanding of the gravity and expected outcome of his particular case. This last factor is of extreme importance because many patients and physicians equate the diagnosis of malignant melanoma with the grim prognosis and outlook for patients as cited in the older literature.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lee, LAH: Melanoma. In: Cancer epidemiology and prevention, Schottenfeld D, Fraumeri JF Jr, (eds). Philadelphia: WB Saunders, 984–985, 1982.
Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry J IV, Witmer WK, Thompson J, Matozzo I, Fraser MC: Acquired precursor or cutaneous malignant melanoma. NEJM 312:91–97, 1985.
Fuen LG, Burgess A, Gutterman J et al: The natural history of Stage IV-A melanoma (abstract). Proc AACR/ASCO 22:472, 1981.
Mundth Ed, Guralnick EA, Raker JW: Malignant melanoma, a clinical study of 427 cases. Ann Surg 162:15–28, 1965.
Balch CM, Soong SJ, Murad TM et al: A multifactorial analysis of melanoma. III. Prognosis factors in melanoma patients with lymph node metastasis (Stage II). Ann Surg 193:377–388, 1981.
Day CL, Harrist TJ, Gorstein et al: Malignant melanoma — prognostic significance of ‘microscopic satellites’ in the reticular dermis and subcutaneous fat. Ann Surg 194:108–112, 1981.
Sugarbaker EV, McBride CM: Melanoma of the trunk: The results of surgical excision and anatomic guidelines for predicting nodal metastases. Surgery 80:22–30, 1976.
Cady B, Legg MA, Redfern AB: Contemporary treatment of malignant melanoma. Am J Surg 129:472–482, 1975.
Block GE, Hartwell SW: Malignant melanoma: A study of 217 cases Ann Surg 154 (Suppl): 74–101, 1964.
Clark WH, From L, Bernardino EA, et al: The histogenesis and histologic behavior of primary human malignant melanoma of the skin. Cancer Res 29:705–715, 1969.
Breslow A: Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908, 1970.
Day CL, Mihm MC Jr, Lew RA et al: Prognostic factors for patients with clinical Stage I melanoma of intermediate thickness (1.51–3.99 mm) Ann Surg 195:35–43, 1981.
Gromet MA, Epstein WL, Blois MS: The regressing thin malignant melanoma. Cancer 42:2282–2292, 1978.
Balch CM, Wilkerson JA, Munrad TM, Soong SJ, Ingalls AL, Maddox WA: The prognostic significance of ulceration of cutaneous melanoma. Cancer 45:3012–3017, 1980.
Day CL, Lew RA, Harrist TJ: Malignant melanoma prognostic factors 4: Ulceration width. J Dermatol Surg Oncol 10:23–24, 1984.
Harrist TJ, Rigel DS, Day CL, et al: ‘Microscopic satellites’ are more highly associated with regional lymph node metastasis than is primary tumor thickness. Cancer 53:2183–2187, 1986.
Lew RA, Day CL, Harrist TJ et al: Multivariate analyses — some guidelines for physicians. JAMA 249:641–643, 1983.
Eldh J, Boeryd B, Peterson LE: Prognostic factors in cutaneous malignant melanoma in Stage I: A clinical, morphological, and multivariate analysis. Scand J Plast Reconstr Surg 12:243–255, 1978.
Cascinelli N, Morabito A, Bufalino R, et al: Prognosis of Stage I melanoma of the skin. Int J Cancer 26:733–739, 1981.
Balch CM, Soong SJ, Murad T, et al: A multifactorial analysis of melanoma: II. Prognostic features of Clinical Stage I disease. Surgery 86:343–351, 1979.
Day CL, Sober AJ, Kopf AW, et al: A prognostic model for Clinical Stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg 193:436–440, 1981.
Day CL, Sober AJ, Kopf AW, et al: A prognostic model for Clinical Stage I melanoma of the lower extremity — location on the foot is an independent risk factor for recurrent disease. Surgery 89:599–603, 1981.
Day CL, Sober AJ, Kopf AW et al: A prognostic model for Clinical Stage I melanoma of the trunk: Location near the midline is not an independent risk factor for recurrent disease. Am J Surg 142:247–251, 1981.
Wanebo HJ, Woodruff J, Fortner JG: Malignant melanoma of the extremities; a clinicopatho-logic study using levels of invasion (microstage) Cancer 35:66, 1975.
Veronesi U, Adannus J, Bandiera DC, et al: Stage I melanoma of the limbs; immediate versus delayed node dissection. Tumori 66:373–379, 1980.
Day CL, Lew RA, Mihm MC Jr., et al: The natural break points for primary tumor thickness in Clinical Stage I melanoma. N Engl J Med 305:1155, 1981.
Day CL, Mihm MC Jr Sober AJ et al: Prognostic factors for melanoma patients with lesions 0.76 through 1.69 mm in thickness: An appraisal of thin Level IV lesions. Ann Surg 195:30–34,
Day CL, Mihm MC Jr, Lew RA, et al: Cutaneous malignant melanoma: Prognostic guidelines for physicians and patients. CA-A Cancer Journal for Clinicians 32:113–122, 1982.
Day CL, Sober AJ, Lew RA, et al: Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in Clinical Stage I melanoma patients with metastases to regional nodes. Cancer 47:955–962, 1981.
Woods JA, Taylor MF, Pritchard DJ, et al: Is the BANS concept of malignant melanoma valid? An J Surg 150:452–455, 1985.
Casinelli N, Vaglini M, Bufaliva R, Morabito A: BANS: A cutaneous region with no prognostic significance in patients with malignant melanoma. Cancer 57:441–444, 1986.
Van Der Esch GP, Cascinelli N, et al: Stage I melanoma of the skin: Evaluation of prognosis according to histologic characteristics. Cancer 48:1668–1673, 1981.
McGovern VJ, Shaw HM, Milton GW, McCarthy WH: Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 6:399–407, 1982.
Day CL, Lew RA, Harrist TJ: Malignant melanoma prognostic factors 4: Ulceration width. J Dermatol Surg Oncol 10:23–24, 1984.
Day CL, Harrist TJ, Lew RA, Mihm MC: Classification of malignant melanomas according to histologic morphology of melanoma nodules. J Dermatol Surg Oncol 8:874–878,900, 1982.
Rhodes AR, Harrist TJ, Day CL, et al: Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Amer A Dermatol 9:563–574, 1983.
Bhan AK, Ruiter DL, Harrist TJ, et al: Major histocompatability antigens and mononuclear inflammatory infiltrate in benign nevomelano-cytic proliferations and malignant melanoma. J Immunol 129:2808–2815, 1982.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Harrist, T.J., Day, C.L. (1987). Malignant Melanoma: Prognostic Factors. In: Nathanson, L. (eds) Basic and Clinical Aspects of Malignant Melanoma. Cancer Treatment and Research, vol 35. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2043-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2043-2_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9215-9
Online ISBN: 978-1-4613-2043-2
eBook Packages: Springer Book Archive